600267.SS
600267.SS
CNE0000013Z2
ZHEJIANG HISUN PHARMACEUTICAL C
Loading chart...

Company Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956 and is headquartered in Taizhou, China.

Related stocks

002399.SZ
002399.SZ • China
HEPALINK
9.89 CNY
2.17B USD 1Y -16.7%
603858.SS
603858.SS • China
SHANDONG BUCHANG PHARMACEUTICAL
14.81 CNY
2.34B USD 1Y -18.9%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
605507.SS
605507.SS • China
GUOBANG PHARMA LTD
17.31 CNY
2.03B USD 1Y +7.4%
603456.SS
603456.SS • China
ZHEJIANG JIUZHOU PHARMACEUTICAL
16.31 CNY
2.14B USD 1Y -20.9%
603707.SS
603707.SS • China
NANJING KING-FRIEND BIOCHEMICAL
8.18 CNY
1.98B USD 1Y -21.6%
600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
600867.SS
600867.SS • China
TONGHUA DONGBAO MEDICINES CO LT
7.88 CNY
2.31B USD 1Y -7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
36.2% p.a.
Max Drawdown (5Y)
-61.6%
Sharpe Ratio (5Y)
-0.08
Beta Factor
0.29
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -68.2% in the extended horizon.
ende